(Reuters) - The European health regulator has vowed to conduct a speedy review of Gilead Sciences'
The European Medicines Agency (EMA) said on Friday its human medicines committee's (CHMP) timeline to assess the drug would be "reduced to the absolute minimum,". (https://bit.ly/2ZPh6HA)
Already a subscriber? Log in.
Limited time offer:
Just RM5 per month.
Cancel anytime. No ads. Auto-renewal. Unlimited access to the web and app. Personalised features. Members rewards.
Follow us on our official WhatsApp channel for breaking news alerts and key updates!